Women with HFrEF do better on lower-dose meds
A sex-specific approach to therapy is needed, researchers say
Women with heart failure achieve significantly better outcomes from half the recommended dose of ACE inhibitors, angiotensin-receptor blockers and beta blockers than men, a Dutch-led study suggests.
The landmark findings, published in the Lancet, challenge the conventional ‘one-size-fits-all’ approach to treating heart failure and could have important implications for sex-specific target doses, the researchers say.
